A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients

Trastuzumab is a standard treatment for HER2-positive (HER2(+)) breast cancer, but some patients are refractory to the therapy. MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2(+) metastatic breast cancer (MBC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huiping, Liu, Jiang, Chen, Jianing, Wang, Huiyun, Yang, Linbin, Chen, Fei, Fan, Siting, Wang, Jing, Shao, Bin, Yin, Dong, Zeng, Musheng, Li, Mengfeng, Li, Jun, Su, Fengxi, Liu, Qiang, Yao, Herui, Su, Shicheng, Song, Erwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915573/
https://www.ncbi.nlm.nih.gov/pubmed/29691399
http://dx.doi.org/10.1038/s41467-018-03537-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915573/
https://www.ncbi.nlm.nih.gov/pubmed/29691399
http://dx.doi.org/10.1038/s41467-018-03537-w

Ejemplares similares